Pediatric hematology/oncology | Stem cell biology | AML | Gene therapy | CRISPR
UT Southwestern
Joined December 2021
- Tweets223
- Following194
- Followers332
- Likes347
Richard Voit retweeted
Inspired by Gibson cloning, we describe prime assembly, now published, for in cellulo targeted integration of gene-sized DNA fragments using prime editing. nature.com/articles/s41586-0…
Richard Voit retweeted
High-risk, high-reward research is our whole mode, including pediatric cancer, where the @DickieV Pediatric Cancer Research Fund helps us fill critical funding gaps.
Richard Voit retweeted
Read this research article by Satish Nandakumar, et al. "Germline noncoding risk variants influence clonal hematopoiesis through altered hematopoietic enhancer activity."aacrjournals.org/bloodcancer…
This article was recently presented by co-author Keisuke Ito at #ISEH2026. @neuron81
Richard Voit retweeted
We cut the ribbon & the Wahlster Lab is officially open! 🎉🔬
#NewPI #NewLab #PediatricCancer #CancerResearch #Hematology #HumanGenetics #Genomics #PhysicianScientist
🙏 to @bloodgenes @BostonChildrens @DanaFarber @BWFUND @ASH_hematology @DamonRunyon – at Boston, MA
Richard Voit retweeted
❓A one-time, durable, and even reversible way to prevent thrombosis? In this preprint, led by @lrbzldz, we show that epigenome editing of 🩸 #StemCells can durably reprogram platelet function: biorxiv.org/content/10.64898…
Richard Voit retweeted
FDA just approved Kresladi (marnetegragene autotemcel) for severe LAD-I — a disease so rare there are ~25 new cases a year in the U.S. The pivotal data: 9 patients. 100% overall survival. All endpoints met. This approval is a masterclass in how to think about evidence standards when mechanism is unambiguous. fda.gov/news-events/press-an…
Richard Voit retweeted
In this piece, my mentor Stu Orkin and I (1) marvel at prime editing—discovery to disease correction for 2 patients after just 6 yr—wow Liu, Anzalone, Gori, Malech et al! & (2) consider the challenges to deliver genetic medicine’s promise for 2^n patients nejm.org/doi/full/10.1056/NE…
Richard Voit retweeted
We fund researchers like @kennethschen, one of the brilliant minds that is helping to shape the future of cancer research. V Foundation researchers, throughout their careers, have generated $22 billion in additional cancer research funding. We truly fund the best of the best.
Richard Voit retweeted
MECOM promotes malignant stem cell–like states in aggressive AMLs by directly repressing prodifferentiation gene regulatory programs. Read the plenary paper in Blood: ow.ly/Nrko50XNqJk #BloodJournal #PlenaryPaper #AML
Richard Voit retweeted
Congrats! 👏👏👏 Two CRI scientists named 2025 Pew-Stewart & Pew Scholars — @JaviGBermudez & @HijaiShin — to advance cancer, biomedical research. Read more about their #relentlessdiscovery ⬇️ cri.utsw.edu/two-childrens-r… @pewtrusts
Richard Voit retweeted
Inspiring piece in @NatureCancer, "An unexpected career in cancer metabolism," highlights Dr. Ralph DeBerardinis & the pivotal moments that prompted him to pursue a career in cancer metabolism. @CRI_UTSW @HHMINEWS nature.com/articles/s43018-0…
Richard Voit retweeted
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia - by
@ShellainaGordon @florian_perner, @Armstrong_dfci, @MAF_Dawson @TheDawsonLab
et al. doi.org/10.1158/2159-8290.CD… @PeterMacRes @DanaFarber
Richard Voit retweeted
KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia
@NMichmerhuizen, Emily Heikamp, @Armstrong_dfci, @CMullighan and colleagues doi.org/10.1158/2159-8290.CD…
@StJudeResearch @DanaFarber
Richard Voit retweeted
Be part of the Wagenblast Lab! We are hiring a Lab Manager for leukemia & blood stem cell research at @IcahnMountSinai in NYC, starting July 2025. See ad to apply!
Richard Voit retweeted
Excited to share with all our latest work on the use of single cell tools in following IDH mutant AML patients during their treatment! Out today @CellStemCell !! An amazing collaboration with @AkEisfeld & @PapaemmanuilLab & @landau_lab !!! Driven by the impressive @MariaSirenko and @soobeomlee & Zhengxi Sun at @NYUGSOM_Path
Richard Voit retweeted
Delighted to have our Perturb-multiome paper, led by @jmartinrufino and #AlexisCaulier from our lab, published today in @ScienceMagazine. Please check out this powerful approach to decipher gene regulatory networks enriched for genetic variation: science.org/doi/10.1126/scie…
Richard Voit retweeted
Congratulations to @DanaFarber’s Lara Wahlster, MD, PhD, and Nina Weichert-Leahey, MD, for receiving the American Society for Clinical Investigation Emerging-Generation Awards. Read about Dr. Wahlster at bit.ly/4haxdTW and Dr. Weichert-Leahey at bit.ly/4h6BYxL.
Richard Voit retweeted
Incredibly proud of @tGaoTeng from our lab, who is a recipient of the @HHMINEWS-@DamonRunyon fellowship!!! Congratulations, Teng!!
damonrunyon.org/news/entries…
Richard Voit retweeted
I am so excited to be selected as one of the recipients of the Michelson Prize from the Michelson Medical Research Foundation and the @ImmunomePro! This award enables our lab's research at the intersection of systems immunology, virology, and large-scale genomics research.
Congratulations to Dr. Caleb Lareau, 2024 #MichelsonPrizes recipient! His work will study the blood virome and answer the critical question: how do humans have vastly different responses to the same infection?
Richard Voit retweeted
Congratulations @LWahlster of @DanaFarber who has been named a 2025 Damon Runyon-St. Jude Pediatric Cancer Research Fellow.
Read more: bit.ly/42T5TWQ
